A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia

Induction of complete remission (CR) is imperative for long-term survival in adult acute lymphoblastic leukemia (ALL) patients regardless of transplantation eligibility. Hyper-CVAD chemotherapy is a widely-used frontline remission induction regimen for these patients. We conducted a pilot trial of f...

Full description

Saved in:
Bibliographic Details
Published inCancer chemotherapy and pharmacology Vol. 81; no. 2; pp. 393 - 398
Main Authors Kim, Sung-Yong, Park, Ji Hyun, Yoon, So Young, Cho, Yo-Han, Lee, Mark Hong
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2018
Springer Nature B.V
Subjects
Acute lymphoblastic leukemia
Adults
Cancer Research
Chemotherapy
Clinical trials
Consolidation
Daunorubicin
Leukemia
Lymphatic leukemia
Medical research
Medicine
Medicine & Public Health
Oncology
Original Article
Patients
Pharmacology/Toxicology
Remission
Survival
Transplantation
Transplants & implants
Adult
Chemotherapy
Daunorubicin
Acute lymphoblastic leukemia
Hyper-CVAD
Remission induction
Online AccessGet full text

Cover

More Information
Summary:Induction of complete remission (CR) is imperative for long-term survival in adult acute lymphoblastic leukemia (ALL) patients regardless of transplantation eligibility. Hyper-CVAD chemotherapy is a widely-used frontline remission induction regimen for these patients. We conducted a pilot trial of frontline remission induction using daunorubicin-augmented hyper-CVAD regimen (hyper-CVDD) in adult ALL patients ( n  = 15). The CR rate after this modified regimen was 100% ( n  = 15). Twelve patients were able to proceed to allogeneic hematopoietic cell transplantation, two patients died before transplantation due to infection, and the remaining one who was ineligible for transplant due to her age received an additional five courses of consolidation chemotherapy. Overall survival (OS) and event-free survival (EFS) of the study patients was 61.0 and 47.5% at 3 years. OS and relapse-free survival of transplanted patients was 66.8 and 55.0% at 3 years. This pilot trial demonstrates the favorable efficacy of the hyper-CVDD chemotherapy as a frontline remission induction regimen. Further clinical trials using this regimen are warranted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-017-3514-3